Multiple Drug Intolerance Syndrome and Arterial Hypertension-Systematic Review and Meta-Analysis

Jakub Rusinek1, Kinga Tyjas2, Wiktoria Ziółek3

  • 1Doctoral School of Medical and Health Sciences, Jagiellonian University Medical College, 31-538 Krakow, Poland.

Journal of Clinical Medicine
|September 13, 2025
PubMed

Insights

Multiple drug intolerance syndrome (MDIS) affects 10% of hypertension patients, leading to uncontrolled blood pressure. Female sex, older age, and mental health conditions are key risk factors for MDIS. Further research is needed.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Arterial hypertension (HT) is a widespread condition linked to significant morbidity and mortality.
  • Multiple drug intolerance syndrome (MDIS), characterized by intolerance to three or more drug classes, complicates HT management.
  • Understanding MDIS prevalence and impact is crucial for improving patient outcomes.

Purpose of the Study:

  • To systematically review and meta-analyze the prevalence of MDIS in patients with hypertension.
  • To investigate the impact of MDIS on hypertension control and identify associated risk factors.

Main Methods:

  • A comprehensive search of major databases (MEDLINE, Scopus, Web of Science, Embase) was conducted in June 2024.
  • Data extraction included MDIS prevalence, risk factors, adverse drug reactions (ADRs), and reaction types.
  • Meta-analysis determined pooled prevalence, adhering to PRISMA guidelines.

Main Results:

  • Four studies comprising 2508 patients were included.
  • The pooled prevalence of MDIS was 10% (95% CI: 4%-19%).
  • Headache (71.47%) and body pain (53.08%) were the most common ADRs. Female sex, older age, gastrointestinal and anxiety disorders were identified as risk factors. Patients with MDIS exhibited higher blood pressure and poorer hypertension control.

Conclusions:

  • MDIS prevalence in hypertensive patients is substantial.
  • Hypertension control is significantly worse in patients with MDIS.
  • Further research is warranted to adequately address this understudied phenomenon.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
942
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.3K
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
471
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.5K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
803
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.3K